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comes of adding biphasic insulin aspart 30 to metformin and
pioglitazone (BIAsp30 + met + pio) compared to maintaining
optimized oral therapy alone (met + pio). METHODS: Treat-
ment efﬁcacy, safety, and baseline demographic data of patients
randomized to either therapy were derived from a recent 34-
week controlled trial (n = 200; mean age 53.8 years; baseline
HbA1c 8.1%; BMI 32.9 kg/m2; 42% male). Over the trial
period, signiﬁcant improvements in HbA1c were demonstrated
for BIAsp30 + met + pio (−1.5 % between arms; p < 0.0001),
though minor hypoglycaemia increased (p < 0.01). A validated
and peer-reviewed economic model utilizing 2nd order Monte-
Carlo simulation with tracker variables and non-parametric
bootstrapping (15 interdependent Markov sub-models of dia-
betes-related complications) calculated life expectancy (LE),
quality-adjusted life expectancy (QALE), incremental cost-effec-
tiveness (ICER), and cumulative complication events over 35
years (base-case). Total management costs were calculated
(annual pharmacy plus complication; US Medicare perspective).
Clinical and cost outcomes were discounted at 3% per annum.
Sensitivity analyses were performed. RESULTS: End-of-study
clinical improvements demonstrated with BIAsp30 were pro-
jected to increase LE (0.66 years), QALE (0.55 quality-adjusted
life years (QALYs)), and reduce cumulative incidences of dia-
betes-related complications, notably retinopathy, renal, and 
cardiovascular disease. An ICER of $22,209/QALY gained was
generated, with an acceptability curve (willingness-to-pay of
$50,000/QALY) portraying BIAsp30 to have a 98.4% probabil-
ity of being cost-effective. Sensitivity analyses supported these
results. CONCLUSION: Type 2 diabetes patients may signiﬁ-
cantly improve glycaemic control with BIAsp30 versus optimiz-
ing oral therapy alone. Through long-term health outcome
projections, BIAsp30 was estimated to improve quality-adjusted
life expectancy and reduce diabetes-related complications in a
cost-effective manner.
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OBJECTIVE: To estimate the cost-effectiveness of inhaled
insulin (INH) in Type 1 (T1DM) and Type 2 diabetes mellitus
(T2DM) patients uncontrolled on current treatment.
METHODS: Cost-effectiveness analysis was conducted from
Swedish health care perspective using the Economic Assessment
of Glycemic control and Long-term Effects of diabetes (EAGLE)
simulation model. EAGLE uses risk equations for the probabil-
ity of micro- and macrovascular complications derived from
UKPDS, WESDR and DCCT. Patient characteristics were
obtained from the Swedish National Diabetes Registry. Compli-
cation costs and health-state utilities were taken from the litera-
ture. Equivalent efﬁcacy was assumed for inhalation and
standard insulin regimens. INH was assumed to result in earlier
initiation or better intensiﬁcation of insulin therapy. Data on
intensiﬁcation inertia were taken from a retrospective study and
intensiﬁcation differential (between INH and standard treat-
ment) was taken from published literature. The analysis was 
performed over a 20 y time-horizon. Costs (SEK2005) and
quality-adjusted life-years (QALYs) were discounted by 3% 
per annum. RESULTS: Treatment costs were higher for all sub-
groups using INH, while the costs of complications were lower,
and survival and utility higher. ICER’s for INH compared to
staying uncontrolled on basal-bolus for T1DM and T2DM were
SEK 38,948 and SEK 151,186/QALY, respectively. In T2DM
patients uncontrolled on °Y´2 orals ICER’s for INH compared to
intensifying to basal or mix-insulin were SEK 178106 and SEK
16,2294/QALY, respectively. For patients uncontrolled on basal
insulin ICER’s for INH compared to intensifying either to mix-
insulin or basal-bolus were 265,376 and 232,442SEK/QALY,
respectively; and in patients on mix-insulin the ICER’s for INH
compared to intensifying to basal-bolus were 183,132SEK/
QALY. Results were robust to changes in discount rate and inten-
siﬁcation differential, although more sensitive to the level of
treatment-associated utilities. CONCLUSION: For T1DM and
T2DM patients uncontrolled on current treatment, a regimen
including INH appears to be cost-effective when taking long-
term micro- and macrovascular outcomes into account.
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OBJECTIVES: The largest proportion of costs in diabetes is due
to complications of the disease. Hypoglycaemia is a common,
chronic complication of drug treatment in diabetes. The aim of
this study was to survey the cost of a major hypoglycaemic event.
METHODS: A systematic literature review was carried out on
all relevant assessments found in published literature. A study
was regarded relevant if it included the cost of a major hypo-
glycaemic event. RESULTS: Relevant studies were found in 
the following countries: Canada, Germany, Sweden, Switzerland,
UK and US. Five studies collected primary data and six studies
based the cost of a hypoglycaemic event on assumptions around
treatment patterns. A major hypoglycaemic event was deﬁned
differently in the different studies. Four studies deﬁned the state
as requiring third-party medical intervention which means assis-
tance from health care services with costs ranging from €293 to
€586. The state was also deﬁned as requiring third party assis-
tance by medical and/or family assistance in four studies, these
estimates ranged from €190 to €1643. One study deﬁned the
state as requiring assistance from another person excluding
medical intervention (€69), while two studies deﬁned the state
from the ICD-9-CM codes, which requires a visit to a health care
provider and presented costs at €950 and €4083, respectively.
The difference in costs between the studies can be explained by
different health care systems, whether direct and/or indirect costs
were included and whether hospitalisation was excluded. Indi-
rect costs were included in three studies. CONCLUSIONS:
Which costs to include in a study is determined by which deﬁn-
ition of a major hypoglycaemic event that is chosen. For this
reason it is important that health economic models apply
matched deﬁnitions to the clinical studies they are modelling.
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OBJECTIVES: The present analysis estimated overall annual
inpatient and outpatient costs incurred by Swedish patients with
diabetes mellitus between 2000 and 2004 based on data from
the RECAP study, which included medical records on 13,873
patients with diabetes mellitus retrospectively identiﬁed in com-
puterised registers at 26 primary care centres in Uppsala county.
Patients included in the study fulﬁlled at least one of the fol-
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lowing three criteria: 1) diagnosis of diabetes mellitus; 2) pre-
scription of oral anti-diabetic drug; and 3) fasting blood or
plasma glucose value indicative of diabetes. The average length
of follow-up upon inclusion was 4.5 years. METHODS: Costs
of inpatient care were estimated by classifying hospitalisations
of study patients into diagnosis-related groups (DRGs) accord-
ing to the Nord-DRG classiﬁcation system and assigning average
costs per DRG (2002 prices) according to a national list relying
on individual patient level costs incurred at Swedish hospitals
applying the Nord-DRG system. Costs of outpatient care were
estimated by assigning unit costs of outpatient care-giver con-
tacts obtained from published sources to data on study patients’
care-giver contacts as recorded in medical records at participat-
ing primary care centres. RESULTS: The average annual cost of
inpatient care over the studied years was €1088 per patient (SD
€4460; n = 9292 on average). Between 2000 and 2004, an annual
increase in costs of between 9% and 15% was observed (con-
stant prices). The average annual cost of outpatient care during
the studied years was €363 per patient (SD €437) with little vari-
ation over the years. GP visits accounted for 40% of outpatient
costs, the average patient making 1.7 GP visits per year. CON-
CLUSIONS: Diabetes continues to impose a heavy economic
burden on society. Cost estimates from this population-based
sample of Swedish diabetic patients may serve as reference values
for a Swedish setting.
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OBJECTIVES: The RESULT study demonstrated that sulphony-
lurea (SU) plus rosiglitazone (RSG) provided a sustained and
substantial increase in beta-cell function (BCF) from baseline
(56%, p < 0.0001) compared to SU alone (6%, p = 0.41). This
modelling study explores the impact on disease progression,
health outcomes and health care expenditure in Portugal of 
different approaches to modelling RSG’s effect on BCF.
METHODS: DiDACT, a peer-reviewed published long-term
model of T2DM, was used to replicate patient characteristics
(73% Male, mean age 68.2 years, mean BMI 30 kg/m2) and the
impact of SU + RSG on BCF observed in the RESULT study using
an additive, a multiplicative or combined approach. Disease pro-
gression for 1000 hypothetical patients, projected total lifetime
health care costs and health gains, measured in time to insulin
and quality-adjusted life years (QALYs) were predicted. Follow-
ing failure of intermediate SU dose to maintain glycaemic target,
up-titrated SU therapy was compared to SU + RSG combination.
The treatment change threshold was HbA1C ≥ 7.5%. Resources
were valued using national unit costs from a variety of sources.
Costs and outcomes were discounted at 5% per year. RESULTS:
Both revised calibrations yielded lower lifetime health care costs
and additional QALYs, compared to the original calibration.
Compared with SU alone both revised calibrations resulted in
lower incremental cost-effectiveness ratios (ICERs). Each repre-
sentation of RSG showed greater time to insulin than SU alone
(13 years); the additive approach substantially extended viabil-
ity of oral therapy to 27.5 years compared to 20 years for mul-
tiplicative and original calibrations. CONCLUSIONS: Each
modelling approach resulted in reduced costs, increased QALYs
and time to insulin when compared with the original calibration.
The use of RSG in the management of T2DM appears to be cost-
effective in all scenarios investigated. Forthcoming long-term
studies of RSG may conﬁrm the impact of RSG on BCF observed
and enable determination of the most appropriate method for
model calibration.
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OBJECTIVES: The co-epidemics of obesity and type II diabetes
and associated complications result in an increasing population
with high risk of serious morbidity, mortality and reduced
quality of life. This analysis has been speciﬁcally developed to
estimate the cost per quality adjusted life year (QALY) gained
with orlistat compared to standard clinical practice (SCP) in a
particularly high-risk diabetic population with morbid obesity
(BMI > 35 kg/m2 and at least one additional CVD risk). In
Norway this is a population with clearly unmet needs for pre-
ventive medical interventions. METHODS: The incremental
cost-utility is calculated in an Excel-model comparing 1 year of
orlistat treatment followed by 9 years of SCP with 10 years of
SCP. The baseline risk is based on the ﬁndings of the UK Pre-
ventive Diabetes Study (UKPDS), adjusted for differences in
BMI. The effects of orlistat and SCP (conservatively assumed
equal to placebo + SCP) on risk factors (BMI, HbA1c, LDL-cho-
lesterol, SBP), are based on results from the relevant randomized
clinical trials. 3 years catch-up of risks after termination of orli-
stat is assumed. UKPDS and the Heart Protection Study provide
assessments of the change in risk associated with change in
HbA1c and the other relevant risk factors. Effects on utility are
based on the results from CODE-2. Direct costs related to the
treatment alternatives and their associated complications are
included from a Norwegian societal perspective. RESULTS: The
expected incremental cost of treating high-risk Norwegian dia-
betic morbid obese patients with orlistat is approximately
€3125/QALY. Extensive one- and multiway sensitivity analyses
using Monte Carlo simulation indicate robustness of the results.
CONCLUSIONS: The results of this model indicate that one
year treatment with orlistat is a highly cost-effective alternative
to SCP for diabetic patients with morbid obesity and additional
CVD risk in Norway.
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OBJECTIVE: To evaluate the inﬂuence of inadequate glycemic
control (IC) in comorbidity and health resource utilization of
type 2 diabetic patients treated in a general practitioner setting.
METHODS: Retrospective observational study (systematic-sam-
pling) of patients older than 18 years, treated in 5 primary care
centres during 2005. The following parameters were evaluated:
IC, deﬁned by HbA1c > 7%; age; sex; comorbidities (hyperten-
sion, hypercholesterolemia, smoking, obesity, ischemic-heart-
disease, cardiovascular event (CVE), COPD, depression,
cardiac-renal-hepatic insufﬁciency, microvascular complica-
tions); clinical parameters (BMI, total-cholesterol, LDL-Friede-
